|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400087423 |
|
最近更新日期: Date of Last Refreshed on: |
2024-07-26 14:50:02 |
|
注册时间: Date of Registration: |
2024-07-26 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
基于MRC框架的促进孕产妇母乳喂养中西医结合干预方案构建与临床评价研究 |
|
Public title: |
Study on the Construction and Clinical evaluation of the intervention Scheme of Integrated Chinese and Western Medicine to promote maternal Breastfeeding based on MRC Framework |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于MRC框架的促进孕产妇母乳喂养中西医结合干预方案构建与临床评价研究 |
|
Scientific title: |
Study on the Construction and Clinical evaluation of the intervention Scheme of Integrated Chinese and Western Medicine to promote maternal Breastfeeding based on MRC Framework |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
马影蕊 |
研究负责人: |
马影蕊 |
|
Applicant: |
Ma Yingrui |
Study leader: |
Ma Yingrui |
|
申请注册联系人电话: Applicant telephone: |
+86 181 0245 8111 |
研究负责人电话:
Study leader's |
+86 181 0245 8111 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
18102458111@163.com |
研究负责人电子邮件: Study leader's E-mail: |
18102458111@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
辽宁省沈阳市皇姑区北陵大街33号 |
研究负责人通讯地址: |
辽宁省沈阳市皇姑区北陵大街33号 |
|
Applicant address: |
33 Beiling Dajie, Huanggu District, Shenyang City, Liaoning Province |
Study leader's address: |
33 Beiling Dajie, Huanggu District, Shenyang City, Liaoning Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
辽宁中医药大学附属医院 |
||
|
Applicant's institution: |
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
辽宁中医药大学附属医院 |
||
|
Affiliation of the Leader: |
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023035FS(KT)-009-02;2023035XZ(KT)-009-03 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
辽宁中医药大学附属医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Affiliated Hospital of Liaoning University of Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-10-20 00:00:00 | ||
|
伦理委员会联系人: |
李晓 |
||
|
Contact Name of the ethic committee: |
Li Xiao |
||
|
伦理委员会联系地址: |
辽宁省沈阳市皇姑区北陵大街33号 |
||
|
Contact Address of the ethic committee: |
33 Beiling Dajie, Huanggu District, Shenyang City, Liaoning Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 181 0245 9168 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
辽宁中医药大学附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
辽宁省沈阳市皇姑区北陵大街33号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
33 Beiling Dajie, Huanggu District, Shenyang City, Liaoning Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
辽宁省科学技术厅创新能力提升联合基金(项目编号:2022-NLTS-13-01) |
||||||||||||||||||||||
|
Source(s) of funding: |
Science and Technology Department of Liaoning Province Innovation Capacity Promotion Joint Fund (Project No. : 2022-NLTS-13-01) |
||||||||||||||||||||||
|
研究疾病: |
无 |
||||||||||||||||||||||
|
Target disease: |
None |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
评价促进孕产妇母乳喂养中西医结合干预方案的有效性、安全性、卫生经济性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the effectiveness, safety and health economy of the intervention program of integrated Chinese and Western medicine to promote maternal breastfeeding. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①孕37周足月的孕妇;(预实验+正式实验) ②年龄≥18周岁;(预实验+正式实验) ③孕期稳定,具有沟通及理解能力;(预实验+正式实验) ④计划在三中心分娩;(正式实验) ⑤有意愿在产后进行母乳喂养。(正式实验) |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Pregnant women who are 37 weeks pregnant and full-term; (Pre-experiment + Formal Experiment) (2) Age≥ 18 years old; (Pre-experiment + Formal Experiment) (3) Stable pregnancy, communication and understanding skills; (Pre-experiment + Formal Experiment) (4) planned delivery in three centers; (Formal Experiment) (5) Willingness to breastfeed after childbirth. (Formal Experiment) |
||||||||||||||||||||||
|
排除标准: |
①既往有认知障碍,精神病史等;(预实验+正式实验) ②孕妇有其他器质性疾病、糖尿病/胰岛素抵抗、多囊卵巢综合征、甲状腺疾病等;(预实验+正式实验) ③孕妇患有HIV/AIDS。(预实验+正式实验) |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Previous cognitive impairment, history of mental illness, etc.; (Pre-experiment + Formal Experiment) (2) Pregnant women have other organic diseases, diabetes/insulin resistance, polycystic ovary syndrome, thyroid diseases, etc.; (Pre-experiment + Formal Experiment) (3) Pregnant women with HIV/AIDS. (Pre-experiment + Formal Experiment) |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-10-21 00:00:00至 To 2025-01-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-10-21 00:00:00 至 To 2024-07-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
预实验采用分层区组随机,正式实验采用动态分层区组随机。 由数据管理方生成随机分配序列,通过SAS9.3统计分析软件实现。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The pre-experiment was randomized by stratified blocks, and the formal experiment was randomized by dynamic stratified blocks. Random assignment sequences are generated by the data manager and implemented by SAS9.3 statistical analysis software. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
仿盲。本研究对结局评估者实施盲法,对受试者实施仿盲,本研究类似于双盲但是在实际操作中达不到真正的双盲,介于单盲与双盲之间,因此本研究为仿双盲。 |
|
Blinding: |
Quasi-blind. In this study, the outcome evaluators were blinded and the subjects were simulated blind. This study was similar to double blind, but it could not reach the real double blind in practice, and it was between single blind and double blind, so this study was simulated double blind. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
ResMan (www.medresman.org.cn) 公共临床试验数据采集和管理系统(EDC系统) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
ResMan (www.medresman.org.cn) Public Clinical Trial Data Acquisition and Management System (EDC System) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表;EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form;EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |